Document:

Exhibit
      4.1

    

    

    

    

    

    February
      27, 2006

    

    Cranshire
      Capital, L.P.

    666
      Dundee Road

    Suite
      1901

    Northbrook,
      Illinois

    USA
      60062

    Attention:    Mitchell
      P. Kopin

    

    

    Dear
      Sirs:

    

    
      	
              Re:

            	
              Generex
                Biotechnology Corporation 

              -
                Amendments to
                Warrants

            

    

    

    We
      make
      reference to (a) the common stock purchase warrant issued by Generex
      Biotechnology Corporation (the “Company”)
      to
      Cranshire Capital, L.P. (“Cranshire”)
      on
      October 20, 2005 pursuant to which the Company granted to Cranshire the
      entitlement to purchase up to 300,000 shares of the Company’s common stock at
      $1.20 per share, (b) the common stock purchase warrant issued by the Company
      to
      Cranshire on October 27, 2005 pursuant to which the Company granted to Cranshire
      the entitlement to purchase up to 309,756 shares of the Company’s common stock
      at $1.25 per share, (c) the common stock purchase warrant issued by the Company
      to Cranshire on October 27, 2005 pursuant to which the Company granted to
      Cranshire the entitlement to purchase up to 304,878 shares of the Company’s
      common stock at $1.25 per share, (d) the common stock purchase warrant issued
      by
      the Company to Cranshire on December 9, 2005 pursuant to which the Company
      granted to Cranshire the entitlement to purchase up to 1,829,268 shares of
      the
      Company’s common stock at $1.25 per share, and (f) the common stock purchase
      warrant issued by the Company to Cranshire on January 20, 2006 pursuant to
      which
      the Company granted to Cranshire the entitlement to purchase up to 952,381
      shares of the Company’s common stock at $1.05 per share (collectively, the
“Warrants”).

    

    The
      Initial Exercise Date (as that term is defined in each of the Warrants) of
      each
      of the Warrants is expressed therein as the 181st
      day
      after the date thereof. The Company hereby confirms that, in consideration
      of
      the exercise by Cranshire of not less than 100% of the Warrants and the delivery
      to the Company of Notices of Exercise in respect thereof on or before the close
      of business on February 27, 2006, the Company has agreed to abridge the Initial
      Exercise Dates and to honor the aforementioned Notices of Exercise.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    In
      addition, the Company will grant to Cranshire an additional common stock
      purchase warrant pursuant to which the Company will grant to Cranshire the
      entitlement to purchase up to 1,848,142 shares of the Company’s common stock at
      $3.00 per share exercisable for a period of five years from and after August
      27,
      2006.

    

    Yours
      truly,

    

    Generex
      Biotechnology Corporation

    

    

    

    /s/
      Mark A. Fletcher                

    Mark
      A.
      Fletcher

    Executive
      Vice-President, General Counsel

    maf:hsExhibit
      4.2

    

    

    

    

    

    February
      27, 2006

    

    Omicron
      Master Trust

    650
      Fifth
      Avenue

    24th
      Floor

    New
      York,
      New York

    USA
      10019

    Attention:         Brian
      Daly

    

    

    Dear
      Sirs:

    

    
      	
              Re:

            	
              Generex
                Biotechnology Corporation

              -
                Amendments to
                Warrants

            

    

    

    We
      make
      reference to (a) the common stock purchase warrant issued by Generex
      Biotechnology Corporation (the “Company”)
      to
      Omicron Master Trust (“Omicron”)
      on
      October 27, 2005 pursuant to which the Company granted to Omicron the
      entitlement to purchase up to 609,756 shares of the Company’s common stock at
      $1.25 per share, (b) the common stock purchase warrant issued by the Company
      to
      Omicron on October 27, 2005 pursuant to which the Company granted to Omicron
      the
      entitlement to purchase up to 304,878 shares of the Company’s common stock at
      $1.25 per share, (c) the common stock purchase warrant issued by the Company
      to
      Omicron on January 20, 2006 pursuant to which the Company granted to Omicron
      the
      entitlement to purchase up to 952,381 shares of the Company’s common stock at
      $1.05 per share, and (d) the common stock purchase warrant issued by the Company
      to Omicron on July 22, 2005 pursuant to which the Company granted to Omicron
      the
      entitlement to purchase up to 243,902 shares of the Company’s common stock at
      $0.82 per share (collectively, the “Warrants”).

    

    The
      Initial Exercise Date (as that term is defined in each of the Warrants) of
      each
      of the Warrants is expressed therein as the 181st
      day
      after the date thereof. The Company hereby confirms that, in consideration
      of
      the exercise by Omicron of not less than 100% of the Warrants and the delivery
      to the Company of Notices of Exercise in respect thereof on or before the close
      of business on February 27, 2006, the Company has agreed to abridge the Initial
      Exercise Dates and to honor the aforementioned Notices of
      Exercise.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    In
      addition, the Company will grant to Omicron an additional common stock purchase
      warrant pursuant to which the Company will grant to Omicron the entitlement
      to
      purchase up to 1,055,459 shares of the Company’s common stock at $3.00 per share
      exercisable for a period of five years from and after August 27,
      2006.

    

    Yours
      truly,

    

    Generex
      Biotechnology Corporation

    

    

    /s/
      Mark A. Fletcher                

    Mark
      A.
      Fletcher

    Executive
      Vice-President, General Counsel

    maf:hsExhibit
      4.3

    

    

    

    

    

    February
      27, 2006

    

    Iroquois
      Capital LP

    641
      Lexington Avenue

    26th
      Floor

    New
      York,
      New York

    USA
      10022

    Attention:         Joshua
      Silverman

    

    

    Dear
      Sirs:

    

    
      	
              Re:

            	
              Generex
                Biotechnology Corporation

              -
                Amendments to
                Warrants

            

    

    

    We
      make
      reference to (a) the common stock purchase warrant issued by Generex
      Biotechnology Corporation (the “Company”)
      to
      Iroquois Capital LP (“Iroquois”)
      on
      October 20, 2005 pursuant to which the Company granted to Iroquois the
      entitlement to purchase up to 609,756 shares of the Company’s common stock at
      $1.20 per share, (b) the common stock purchase warrant issued by the Company
      to
      Iroquois on October 27, 2005 pursuant to which the Company granted to Iroquois
      the entitlement to purchase up to 304,878 shares of the Company’s common stock
      at $1.25 per share, and (c) the common stock purchase warrant issued by the
      Company to Iroquois on January 20, 2006 pursuant to which the Company granted
      to
      Iroquois the entitlement to purchase up to 952,381 shares of the Company’s
      common stock at $1.05 per share (collectively, the “Warrants”).

    

    The
      Initial Exercise Date (as that term is defined in each of the Warrants) of
      each
      of the Warrants is expressed therein as the 181st
      day
      after the date thereof. The Company hereby confirms that, in consideration
      of
      the exercise by Iroquois of not less than 100% of the Warrants and the delivery
      to the Company of Notices of Exercise in respect thereof on or before the close
      of business on February 27, 2006, the Company has agreed to abridge the Initial
      Exercise Dates and to honor the aforementioned Notices of
      Exercise.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    In
      addition, the Company will grant to Iroquois an additional common stock purchase
      warrant pursuant to which the Company will grant to Iroquois the entitlement
      to
      purchase up to 933,508 shares of the Company’s common stock at $3.00 per share
      exercisable for a period of five years from and after August 27,
      2006.

    

    Yours
      truly,

    

    Generex
      Biotechnology Corporation

    

    

    

    /s/
      Mark A. Fletcher                

    Mark
      A.
      Fletcher

    Executive
      Vice-President, General Counsel

    maf:hsExhibit
      4.4

    

    

    

    

    

    

    February
      27, 2006

    

    Smithfield
      Fiduciary LLC

    c/o
      Highbridge Capital Management, LLC

    9
      West
      57th
      Street

    27th
      Floor

    New
      York,
      New York

    USA
      10019

    Attention:        Ari
      J. Storch / Adam J. Chill

    

    

    Dear
      Sirs:

    

    
      	
              Re:

            	
              Generex
                Biotechnology Corporation

              -
                Amendments to
                Warrants

            

    

    

    We
      make
      reference to (a) the common stock purchase warrant issued by Generex
      Biotechnology Corporation (the “Company”)
      to
      Smithfield Fiduciary LLC (“Smithfield”)
      on
      October 27, 2005 pursuant to which the Company granted to Smithfield the
      entitlement to purchase up to 609,756 shares of the Company’s common stock at
      $1.25 per share, (b) the common stock purchase warrant issued by the Company
      to
      Smithfield on October 27, 2005 pursuant to which the Company granted to
      Smithfield the entitlement to purchase up to 304,878 shares of the Company’s
      common stock at $1.25 per share, and (c) the common stock purchase warrant
      issued by the Company to Smithfield on January 20, 2006 pursuant to which the
      Company granted to Smithfield the entitlement to purchase up to 952,381 shares
      of the Company’s common stock at $1.05 per share (collectively, the
“Warrants”).

    

    The
      Initial Exercise Date (as that term is defined in each of the Warrants) of
      each
      of the Warrants is expressed therein as the 181st
      day
      after the date thereof. The Company hereby confirms that, in consideration
      of
      the exercise by Smithfield of not less than 100% of the Warrants and the
      delivery to the Company of Notices of Exercise in respect thereof on or before
      the close of business on February 27, 2006, the Company has agreed to abridge
      the Initial Exercise Dates and to honor the aforementioned Notices of
      Exercise.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    In
      addition, the Company will grant to Smithfield an additional common stock
      purchase warrant pursuant to which the Company will grant to Smithfield the
      entitlement to purchase up to 933,508 shares of the Company’s common stock at
      $3.00 per share exercisable for a period of five years from and after August
      27,
      2006.

    

    Yours
      truly,

    

    Generex
      Biotechnology Corporation

    

    

    /s/
      Mark A. Fletcher             

    Mark
      A.
      Fletcher

    Executive
      Vice-President, General Counsel

    maf:hs

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00098-of-00352.parquet"}]]